An 8 panel drug test screens urine, oral fluid or a dip card for eight drug classes in a single device. It sits between the federal 5 panel used in regulated safety sensitive jobs and the broader 10 or 12 panel cups that clinics and treatment programs often prefer. There is no single federal standard that defines "8 panel," so the exact analyte list varies by manufacturer and by the employer or clinic ordering it. This guide covers the common configuration, typical screening cutoffs, rough detection windows, who tends to buy an 8 panel test, and why a positive screen is never the final word.
The common 8 panel configuration
Most 8 panel cups and dip cards build out from the five drug classes named in the federal Mandatory Guidelines for workplace drug testing and add three more. The core eight typically are:
- AMP, amphetamines
- BAR, barbiturates
- BZO, benzodiazepines
- COC, cocaine metabolite
- MET, methamphetamine
- OPI, opiates
- PCP, phencyclidine
- THC, marijuana metabolite
AMP, COC, MET, OPI, PCP and THC are the six analytes carried over from the federal five panel structure (methamphetamine and amphetamine are reported together under the amphetamines class). BAR and BZO are the two most common additions. Some manufacturers swap in MTD (methadone), OXY (oxycodone) or BUP (buprenorphine) instead of barbiturates or benzodiazepines, depending on what a clinic or employer is trying to catch. Because "8 panel" is a configuration name, not a regulatory category, buyers should always check the printed analyte list and cutoff on the device insert rather than assume which eight drugs are included.
No rapid panel, 8 panel or otherwise, tests for a substance that is not built into that specific strip. A kratom strip (KRA, mitragynine) is a separate test and is not part of a standard 8 panel. Emerging opioid analogs are generally not detected by immunoassay panels at all; a lab confirmation test is the only way to check for those, and the ordering party should ask the lab which analytes its confirmation method actually covers.
Typical screening cutoffs and detection windows
The table below lists common urine immunoassay screening cutoffs. These reflect the pattern used in the federal Mandatory Guidelines for the five analytes that overlap with the federal panel, published in the Federal Register Mandatory Guidelines for Federal Workplace Drug Testing Programs; cutoffs for BAR and BZO are common industry defaults and are not set by that federal rule, since barbiturates and benzodiazepines are not part of the federal five panel. A non federal employer, clinic or lab can set its own cutoff within what the device manufacturer validates, so always confirm the cutoff printed on the specific product insert.
| Analyte | Typical screening cutoff | Approximate detection window in urine |
|---|---|---|
| Amphetamines (AMP) | 1000 ng/mL (500 ng/mL variants exist) | 1 to 3 days |
| Barbiturates (BAR) | 300 ng/mL | 1 to 3 days (short acting), up to several weeks (long acting) |
| Benzodiazepines (BZO) | 300 ng/mL | 1 to 7 days (varies widely by specific drug) |
| Cocaine metabolite (COC) | 150 ng/mL | 2 to 4 days |
| Methamphetamine (MET) | 500 ng/mL | 2 to 5 days |
| Opiates (OPI) | 2000 ng/mL | 1 to 3 days (varies by specific opiate) |
| Phencyclidine (PCP) | 25 ng/mL | up to 7 to 14 days |
| Marijuana metabolite (THC) | 50 ng/mL | a few days for occasional use, longer with frequent use |
Detection windows vary by individual metabolism, hydration, frequency of use and the specific drug within a class, so these ranges are general guidance, not a guarantee for any one test taker. A full federal cutoff reference, including confirmation cutoffs, is in our SAMHSA and DOT drug testing cutoff levels reference.
Screening versus confirmation
An 8 panel cup or dip card runs an immunoassay, a rapid chemical screen that gives a presumptive result, not a confirmed diagnosis. A non negative screen on any analyte should be sent to a certified laboratory for confirmation, typically by gas chromatography mass spectrometry or liquid chromatography mass spectrometry. Confirmation testing identifies the specific drug and metabolite rather than a drug class, and it is what distinguishes a true positive from a false positive caused by cross reactivity with an unrelated compound. The federal Mandatory Guidelines build this two step screen and confirm structure into regulated testing, and most non regulated employers and clinics follow the same practice as a matter of program integrity, even though they are not legally required to under a federal mandate.
Any employer running a federally regulated safety sensitive testing program under 49 CFR Part 40 must use a Medical Review Officer (MRO) to review any non negative confirmed result before it is reported. The MRO contacts the employee, reviews any current prescription for a legally prescribed controlled substance, and determines whether a legitimate medical explanation accounts for the result. Non regulated employers using an 8 panel for a drug free workplace policy generally are not required to use an MRO, but routing non negative results through a qualified reviewer and documenting prescription information is the practice SAMHSA recommends for program defensibility, outlined on the SAMHSA workplace programs page. Because rules on reviewer requirements and documentation vary by state and by industry, employers should confirm current requirements with their state labor agency or counsel rather than assume a federal standard applies.
Who chooses an 8 panel test
The federal five panel is fixed by regulation for employers covered by DOT rules (49 CFR Part 40), so those employers may not substitute an 8 panel for their regulated testing. Outside that regulated space, an 8 panel is a common middle ground for:
- Non DOT employers who want broader coverage than the federal five but do not need a full 10, 12 or higher panel
- Substance use treatment programs and sober living facilities that monitor for sedatives (BAR, BZO) alongside the core drug classes
- Staffing agencies and light industrial employers doing pre employment and random screening under a company drug free workplace policy
- Pain management and primary care clinics that want a quick point of care check alongside, not instead of, a lab based medication monitoring panel
Choosing between a 5, 8, 10 or 12 panel comes down to what an employer's or clinic's policy and risk profile call for, since adding analytes adds cost and complexity without automatically adding legal protection. Employers weighing that tradeoff may find our 9 panel drug test guide useful for comparing one step up from the 8 panel configuration.
Compliance notes for employers
A drug test result, whether screened or confirmed, is only one input into an employment decision, and how it can be used varies by state. Some states regulate what an employer may do with a positive result for a legally used substance, particularly medical marijuana, and require specific notice or appeal procedures before an adverse action. Employers should treat any multi state workforce as a multi state compliance question and confirm current rules with their state labor department rather than apply one state's rule everywhere. No drug test, panel size, or device description should be marketed as certain or legally conclusive; a rapid panel gives a presumptive screening result only.
Frequently asked questions
What does an 8 panel drug test typically screen for?
Most 8 panel configurations screen for amphetamines, barbiturates, benzodiazepines, cocaine metabolite, methamphetamine, opiates, phencyclidine and marijuana metabolite, though some manufacturers substitute methadone, oxycodone or buprenorphine for one of the eight. Always check the specific product insert.
Is an 8 panel drug test the same as the federal five panel?
No. The federal five panel, used for DOT regulated safety sensitive testing under 49 CFR Part 40, covers amphetamines, cocaine, marijuana, opiates and phencyclidine. An 8 panel adds three more analyte groups and is used by non DOT employers and clinics, not as a substitute for regulated federal testing.
Does a non negative 8 panel screen mean the person used drugs?
Not by itself. A screening result is presumptive. It should be confirmed by a certified laboratory using mass spectrometry before any action is taken, and any legally prescribed medication should be reviewed, generally through a Medical Review Officer process or an equivalent documented review.
Can an 8 panel test detect kratom or newer synthetic opioids?
No. Standard 8 panel strips do not include a kratom (mitragynine) analyte or most newer synthetic opioid analogs. Detecting those substances requires a dedicated strip or a laboratory confirmation test, and buyers should ask the lab which specific analytes its confirmation panel covers.
Who typically buys 8 panel drug tests?
Non DOT employers, staffing agencies, substance use treatment programs, sober living facilities and some clinics commonly choose an 8 panel as a middle option between the federal five panel and broader 10 or 12 panel cups.
What cutoff levels apply to an 8 panel test?
Cutoffs vary by manufacturer and analyte; common urine screening cutoffs include 1000 ng/mL for amphetamines, 300 ng/mL for barbiturates and benzodiazepines, 150 ng/mL for cocaine metabolite, 500 ng/mL for methamphetamine, 2000 ng/mL for opiates, 25 ng/mL for PCP and 50 ng/mL for THC. The cutoff printed on the specific device insert governs, since not every manufacturer uses identical cutoffs.
Browse 8 panel and multi panel drug test cups from American Screening Corporation.
This article is general information for employers and clinics, not legal or medical advice. Drug testing program requirements vary by state and industry; consult qualified counsel or a Medical Review Officer for guidance specific to your program.
